{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:29:03Z","timestamp":1786418943831,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacadv.2026.102633","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:16:10Z","timestamp":1774466170000},"page":"102633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiplatelet Therapy in Stable Coronary Artery Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Rawan Mohammed","family":"Alzahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terad","family":"Talmesany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheer Atiah","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheer Fawaz","family":"Alhamyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danah Abdulaziz","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama Saleh","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miad Abdullah","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaima Dhaher","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K.","family":"Alsaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Y.","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102633_bib1","first-page":"376","article-title":"Stable coronary artery disease: treatment","volume":"97","author":"Braun","year":"2018","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jacadv.2026.102633_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40292-021-00497-z","article-title":"Contemporary management of stable coronary artery disease","volume":"29","author":"Bertolone","year":"2022","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.jacadv.2026.102633_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40119-022-00255-9","article-title":"Coronary artery disease and aspirin intolerance: background and insights on current management","volume":"11","author":"Thakker","year":"2022","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jacadv.2026.102633_bib4","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib5","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2021.1527","article-title":"Diagnosis and management of stable angina: a review","volume":"325","author":"Joshi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.102633_bib6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s11883-024-01234-2","article-title":"Should we use aspirin or P2Y12 inhibitor monotherapy in stable ischemic heart disease?","volume":"26","author":"Chandiramani","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacadv.2026.102633_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0115701611269735231106110250","article-title":"P2Y12 inhibitor or aspirin monotherapy in patients with coronary artery disease: is it time for a paradigm shift?","volume":"22","author":"Gragnano","year":"2024","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacadv.2026.102633_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s12471-022-01672-0","article-title":"Using real-world data to monitor and improve quality of care in coronary artery disease: results from the Netherlands heart registration","volume":"30","author":"Timmermans","year":"2022","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jacadv.2026.102633_bib9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/clc.23898","article-title":"Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: \u201cReal-world\u201d evidence","volume":"45","author":"Chen","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacadv.2026.102633_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12325-021-01987-1","article-title":"Clinical implications of nicorandil combined with trimetazidine in patients with coronary heart disease: a real-world observational study","volume":"39","author":"Shen","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacadv.2026.102633_bib11","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102633_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102633_bib13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","article-title":"Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease: meta-analysis of randomized trials","volume":"85","author":"Rashedi","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102633_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241244772","article-title":"Efficacy and safety of long-term dual antiplatelet therapy: a systematic review and meta-analysis","volume":"30","author":"Zhang","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jacadv.2026.102633_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/clc.70026","article-title":"Meta-analysis comparing oral anticoagulant monotherapy versus dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease","volume":"47","author":"Ahmed","year":"2024","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacadv.2026.102633_bib16","series-title":"Fewer drugs, less bleeding in atrial fibrillation with stable coronary artery disease: less is more","first-page":"1204","author":"Shurrab","year":"2025"},{"key":"10.1016\/j.jacadv.2026.102633_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001707","article-title":"Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials","volume":"8","author":"Bularga","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.jacadv.2026.102633_bib18","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102633_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019184","article-title":"Efficacy and safety of long-term antithrombotic strategies in patients with chronic coronary syndrome: a network meta-analysis of randomized controlled trials","volume":"10","author":"Zhu","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2026.102633_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/1570161118666200820141131","article-title":"Efficacy and safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic review and network meta-analysis","volume":"19","author":"De Carlo","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacadv.2026.102633_bib21","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1111\/bcp.15221","article-title":"Antiplatelet therapy in cardiovascular disease: current status and future directions","volume":"88","author":"Passacquale","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacadv.2026.102633_bib22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.amjcard.2019.05.072","article-title":"Meta-analysis of oral anticoagulant monotherapy as an antithrombotic strategy in patients with stable coronary artery disease and nonvalvular atrial fibrillation","volume":"124","author":"Lee","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2026.102633_bib23","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1007\/s12325-019-01004-6","article-title":"Aspirin versus clopidogrel monotherapy for the treatment of patients with stable coronary artery disease: a systematic review and meta-analysis","volume":"36","author":"Yuan","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacadv.2026.102633_bib24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jacadv.2026.102633_bib25","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20240202i","article-title":"Fixed-dose antiplatelet dual combination in patients with coronary artery disease in Turkish population: DAPT-TR","volume":"121","author":"\u00d6z","year":"2024","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.jacadv.2026.102633_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118589","article-title":"Recurrent cardiovascular and limb events in 294,428 patients with coronary or peripheral artery disease or ischemic stroke on antiplatelet monotherapy: the RESRISK cohort study","volume":"398","author":"Vallejo-Vaz","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2026.102633_bib27","first-page":"253","volume":"04","author":"Bian","year":"2024"},{"key":"10.1016\/j.jacadv.2026.102633_bib28","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1183839","article-title":"Incidence and impact of antiplatelet therapy cessation among very older patients with stable coronary artery disease","volume":"14","author":"Zou","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacadv.2026.102633_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.athoracsur.2021.03.061","article-title":"Ticagrelor or aspirin after coronary artery bypass in patients with chronic kidney disease","volume":"113","author":"Sandner","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacadv.2026.102633_bib31","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jacadv.2026.102633_bib32","article-title":"Optimal medical therapy in patients with stable coronary artery disease in Poland: the ISCHEMIA trial experience","volume":"131","author":"Praco\u0144","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib33","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacadv.2026.102633_bib34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib35","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.jacc.2021.03.298","article-title":"Diabetes-related factors and the effects of ticagrelor plus aspirin in the THEMIS and THEMIS-PCI trials","volume":"77","author":"Leiter","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102633_bib36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","article-title":"Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease","volume":"138","author":"Orme","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102633_bib38","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib39","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102633_bib41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.amjmed.2014.09.028","article-title":"Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort","volume":"128","author":"Bavry","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib42","article-title":"Calprotectin and platelet aggregation in patients with stable coronary artery disease","volume":"10","author":"Larsen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacadv.2026.102633_bib43","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a Nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102633_bib44","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib45","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102633_bib46","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib47","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee","volume":"348","year":"1996","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jacadv.2026.102633_bib48","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.2147\/IJGM.S383485","article-title":"Comparison of aspirin and rivaroxaban plus aspirin in the management of stable coronary artery disease or peripheral artery disease: a systematic review of randomized controlled trials","volume":"15","author":"Debasu","year":"2022","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.jacadv.2026.102633_bib49","article-title":"Global antiplatelet sales trend: a focus on P2Y12 inhibitors from 2008 to 2018","volume":"4","author":"Ye","year":"2021","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.jacadv.2026.102633_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.48389","article-title":"Ticagrelor vs prasugrel for acute coronary syndrome in routine care","volume":"7","author":"Kr\u00fcger","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacadv.2026.102633_bib51","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00380-024-02428-z","article-title":"Clinical impact of academic research consortium for high bleeding-risk scores on clinical outcomes in patients with stable coronary artery disease undergoing percutaneous coronary intervention","volume":"39","author":"Shimono","year":"2024","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacadv.2026.102633_bib52","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023578","article-title":"How do lipoprotein(a) concentrations affect clinical outcomes for patients with stable coronary artery disease who underwent different dual antiplatelet therapy after percutaneous coronary intervention?","volume":"11","author":"Cui","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2026.102633_bib53","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s40265-020-01397-7","article-title":"Rivaroxaban: a review for secondary CV prevention in CAD and PAD","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jacadv.2026.102633_bib54","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/14656566.2024.2427338","article-title":"Reassessing the role of aspirin in patients with coronary artery disease","volume":"25","author":"Tantry","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacadv.2026.102633_bib55","article-title":"Efficacy and safety of extended antithrombotic therapy in stable coronary artery disease: systematic review of the literature","volume":"12","author":"Lemus-Barrios","year":"2024","journal-title":"Med Res Arch"},{"key":"10.1016\/j.jacadv.2026.102633_bib56","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.15419\/bmrat.v11i5.888","article-title":"Platelet reactivity in patients with coronary artery disease undergoing dual antiplatelet therapy with aspirin and clopidogrel","volume":"11","author":"Nguyen","year":"2024","journal-title":"Biomed Res Ther"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:49:49Z","timestamp":1786416589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2772963X26000505"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102633","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet Therapy in Stable Coronary Artery Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102633"}}